Which specific drugs and manufacturers agreed to TrumpRx pricing and what are the exact price changes?

1. Who signed on and the scope of the deals

The White House named nine participating manufacturers — Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche), Gilead, GSK, Merck, Novartis and Sanofi — and framed the commitments as reductions for Medicaid and for cash-paying patients buying directly through TrumpRx, plus pledges of U.S. manufacturing investment and API donations; independent outlets confirm the same nine companies and add that prior agreements had been reached with Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk ^{[4] [1] [5] [2]}.

2. The clearest, named price cuts — drug, manufacturer and exact change

The administration and reporting provide several explicit examples: Sanofi’s Plavix (a blood thinner) will be offered through TrumpRx at $16 versus a cited list price of $756, and Sanofi said its insulin products would be listed at $35 per month’s supply on TrumpRx ^[4]. Gilead’s hepatitis C cure Epclusa was announced to drop to $2,425 from $24,920 on TrumpRx ^{[6] [7]}. Merck said it would reduce the price of its diabetes drug Januvia on TrumpRx to $100 from $330 ^[6]. GSK committed to offering its Advair Diskus 500/50 inhaler at $89 instead of $265 through TrumpRx ^{[6] [8]}. Amgen cited percentage discounts for two medicines in its direct-to-patient expansion — Aimovig (migraine prevention) at roughly a 60% discount and Amjevita (autoimmune) at roughly an 80% discount — though Amgen’s announcement in reporting gave percentage reductions rather than fixed per-unit prices ^[5].

3. What is not disclosed or remains ambiguous

Despite those headline examples, multiple outlets and the White House note that many individual terms were not publicly disclosed and that companies typically give substantial off-invoice discounts to payers, so the real-world impact depends on program design and participation; Reuters, the Times and AJMC all report that many price terms were left unspecified and that the deals often cover Medicaid and cash-pay channels rather than private insurance formularies ^{[9] [2] [10]}. Several reports also caution that list-price cuts announced for TrumpRx are limited to direct-to-consumer or Medicaid sales and do not automatically change pricing under commercial insurance or Medicare unless separately negotiated ^{[10] [9]}.

4. Incentives, tradeoffs and the administration’s leverage

Reporting makes clear the deals were struck in exchange for policy incentives — notably a three-year reprieve from threatened pharmaceutical tariffs and other concessions — and the administration framed investment commitments (a combined $150 billion pledge) and API donations as part of the bargain; analysts and editorial writers warn those tradeoffs could shift where costs fall internationally or have longer-term effects on innovation, with critics saying the approach sidesteps systemic pricing reforms ^{[5] [10] [7] [11]}.

5. Bottom line and limits of reporting

The definitive list of companies involved is consistent across government and press accounts, and several specific price changes were publicly cited (Sanofi: Plavix $756 → $16 and insulin $35/mo; Gilead: Epclusa $24,920 → $2,425; Merck: Januvia $330 → $100; GSK: Advair Diskus $265 → $89; Amgen: Aimovig ~60% and Amjevita ~80% discounts), but many products and exact prices were not disclosed in the announcements, meaning the full roster of drugs and all exact price changes for each manufacturer remain incompletely documented in public reporting ^{[4] [6] [5] [8] [9]}. Alternative perspectives are present in the coverage: the administration and companies present immediate patient savings and manufacturing investment, while critics and economists warn about limited scope (cash/Medicaid only), possible downstream effects on innovation and the use of tariff threats as leverage ^{[4] [11] [10]}.